INVESTOR OVERVIEW Corporate profile Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential […]
CORPORATE GOVERNANCE Documents & Charters Audit Committee Charter Compensation Committee Charter Nominating & Corporate Governance Committee Charter Code of Business Conduct & Ethics Corporate Governance Guidelines Other Links View Our Management View Our Board of Directors Committee Composition Audit Compensation Nominating and Corporate Governance Committee Daniel Zabrowski Chair Member Roger Sawhney Member Member Amy Ronneberg
Corporate Governance Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 – 6, 2023, in Chicago, Illinois. The abstracts are currently available on the ASCO meeting website. The
ACTUATE THERAPEUTICS ANNOUNCESPOSTER PRESENTATIONS AT THE 2023 ASCO ANNUAL MEETING Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida. The abstracts are currently available on the AACR meeting website. The posters will
ACTUATE THERAPEUTICS ANNOUNCES POSTER PRESENTATIONS AT THE 2023 AACR ANNUAL MEETING Read More »
CHICAGO, IL and FORT WORTH, TX, March 23, 2023 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been elected as President-Elect of the American Association of Cancer Research for
COOKIE POLICY Cookies are small text files that are placed on your device by websites that you visit. They are used to make websites work, or work more efficiently, as well as to provide information to the owners of the website. Our website uses strictly necessary cookies, functional cookies and tracking and performance cookies. Strictly
ACCESSIBILITY STATEMENT OUR COMMITMENT TO ACCESSIBILITY Actuate is committed to making our website accessible to everyone. We have built our website in a manner to work with assistive technologies using the Worldwide Web Consortium’s Website Content Accessibility Guidelines. Actuate continues to evaluate its website to maintain and expand its accessibility for all visitors. FEEDBACK If
CONTACT US If you would like to partner with us, have media inquiries, or simply want to learn more, we want to hear from you. Fill out the form below to get in touch. US ADDRESS 1751 River Run, Suite 400 Fort Worth, TX 76107 EMAIL info@actuatetherapeutics.com EU ADDRESS The Black Church St. Mary’s Place
CAREERS We are pushing further, discovering more, and redefining treatment expectations for patients and providers. But as passionate as we are about our work, we’re equally passionate about doing everything with integrity, ethics, and inclusion. Careers We live, breathe, and sleep scientific innovation. It’s the “why” behind everything we do. If you are driven by
